The University of Chicago Header Logo

Connection

Mark Kozloff to Colorectal Neoplasms

This is a "connection" page, showing publications Mark Kozloff has written about Colorectal Neoplasms.
Connection Strength

1.720
  1. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Dec; 12(4):248-54.
    View in: PubMed
    Score: 0.256
  2. Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'. Oncology. 2011; 80(1-2):135-7; author reply 140-1.
    View in: PubMed
    Score: 0.219
  3. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010; 78(5-6):329-39.
    View in: PubMed
    Score: 0.207
  4. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009 Sep; 14(9):862-70.
    View in: PubMed
    Score: 0.193
  5. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008 Nov 20; 26(33):5326-34.
    View in: PubMed
    Score: 0.182
  6. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022 Sep; 18(27):3011-3020.
    View in: PubMed
    Score: 0.118
  7. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.
    View in: PubMed
    Score: 0.094
  8. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist. 2017 03; 22(3):264-271.
    View in: PubMed
    Score: 0.081
  9. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf. 2014 Jul; 23(7):726-34.
    View in: PubMed
    Score: 0.067
  10. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol). 2014 Jun; 26(6):323-32.
    View in: PubMed
    Score: 0.066
  11. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer. 2013 Dec 15; 119(24):4290-8.
    View in: PubMed
    Score: 0.064
  12. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17(12):1486-95.
    View in: PubMed
    Score: 0.060
  13. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012 May; 48(8):1126-32.
    View in: PubMed
    Score: 0.058
  14. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.